Skip to main content
. 2024 Jun 13;134(15):e165734. doi: 10.1172/JCI165734

Figure 3. Lin28b is indispensable for NRASG12V/Tp53-driven liver cancer development.

Figure 3

(A) Representative gross images of Tp53-KO (Albumin-Cre; Tp53fl/fl; n = 4), Lin28a/Tp53-DKO (Albumin-Cre; Tp53fl/fl; Lin28afl/fl; n = 5), and Lin28b/Tp53-DKO (Albumin-Cre; p53fl/fl; Lin28bfl/fl; n = 4) mice that received NRASG12V by HDT for 7 weeks. Scale bars: 1 cm; 5 mm (right panels). (B) Liver-to-body weight ratios for A. One-way ANOVA was performed. (C) Representative gross images of Lin28a/Lin28b/Tp53-TKO mice that received NRASG12V in combination with pT3-eGFP (n = 5), pT3-LIN28A (n = 8), or pT3-LIN28B (n = 3) for 7 weeks. Scale bars: 1 cm; 5 mm (right panels). (D) Liver-to-body weight ratios for C. One-way ANOVA was performed. (E) Representative gross images of Lin28a/Lin28b/Tp53-TKO mice that received NRASG12V combined with pCMV-eGFP (n = 4) or pCMV-LIN28B (n = 4) for 7 weeks. Scale bars: 1 cm; 5 mm (right panels). (F) Liver-to-body weight ratios for E. **P < 0.01; ***P < 0.001.